Escitalopram 5/10/20 mg tabs — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Generalized Anxiety Disorder / Panic Disorder

• Buspirone
• Sertraline
• Buspirone 5/10/15/30 mg tabs
• Sertraline 25/50/100 mg tabs

What Escitalopram 5/10/20 mg tabs is approved for (FDA label)

Escitalopram tablets are indicated for the treatment of: major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. generalized anxiety disorder (GAD) in adults. Additional pediatric use information is approved for AbbVie Inc.'s LEXAPRO (escitalopram) tablets. However, due to AbbVie Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Escitalopram tablets are a selective serotonin reuptake inhibitor (SSRI) indicated for: treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older ( 1 ) treatment of generalized anxiety disorder (GAD) in adults ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Escitalopram 5/10/20 mg tabs (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [ see Warnings and Precautions ( 5.1 ) ]. Escitalopram tablets are not approved for use in pediatric patients less than 12 years of age [ see Use in Specific Populations ( 8.4 ) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Escitalopram tablets is not approved for use in pediatric patients less than 7 years of age ( 8.4 ).

Source: FDA prescribing information (DailyMed). Set ID: d75e3b97-1ead-4e7b-9ae3-3626aede1efd. SPL document ID: 5a9933f1-4dfa-bb02-e063-6394a90a1c2d. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Escitalopram 5/10/20 mg tabs (FDA label)

Tablets Escitalopram Tablets, USP 5 mg are available as White, round, biconvex, film coated tablets, engraved "77" on one side and plain on the other side. Tablets: 5 mg

Source: FDA prescribing information (DailyMed). Set ID: d75e3b97-1ead-4e7b-9ae3-3626aede1efd. SPL document ID: 5a9933f1-4dfa-bb02-e063-6394a90a1c2d. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Escitalopram 5/10/20 mg tabs (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: Suicidal thoughts and behaviors in adolescents and young adults [see Warnings and Precautions ( 5.1 )] Serotonin syndrome [see Warnings and Precautions ( 5.2 )] Discontinuation syndrome [see Warnings and Precautions ( 5.3 )] Seizures [see Warnings and Precautions ( 5.4 )] Activation of mania or hypomania [see Warnings and Precautions ( 5.5 )] Hyponatremia [see Warnings and Precautions ( 5.6 )] Increased Risk of Bleeding [see Warnings and Precautions ( 5.7 )] Interference with Cognitive and Motor Performance [see Warnings and Precautions ( 5.8 )] Angle-closure glaucoma [see Warnings and Precautions ( 5.9 )] Use in Patients with Concomitant Illness [see Warnings and Precautions ( 5.10 )] Sexual Dysfunction [see Warnings and Precautions ( 5.11 )] Most commonly observed adverse reactions (incidence ≥ 5% and at least twice the incidence of placebo patients) are: insomnia, ejaculation disorder (primarily ejaculatory delay), nausea, sweating increased, fatigue and somnolence, decreased libido, and anorgasmia ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: d75e3b97-1ead-4e7b-9ae3-3626aede1efd. SPL document ID: 5a9933f1-4dfa-bb02-e063-6394a90a1c2d. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Escitalopram 5/10/20 mg tabs (FDA label)

Escitalopram tablets is contraindicated in patients: taking MAOIs with Escitalopram tablets or within 14 days of stopping treatment with Escitalopram tablets because of an increased risk of serotonin syndrome. The use of Escitalopram tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration ( 2.7 ) and Warnings and Precautions ( 5.2 )]. Starting Escitalopram tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ) and Warnings and Precautions ( 5.2 )]. taking pimozide [see Drug Interactions ( 7 )]. with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in Escitalopram tablets.

Source: FDA prescribing information (DailyMed). Set ID: d75e3b97-1ead-4e7b-9ae3-3626aede1efd. SPL document ID: 5a9933f1-4dfa-bb02-e063-6394a90a1c2d. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Escitalopram 5/10/20 mg tabs (FDA label)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue Escitalopram tablets and initiate supportive treatment ( 4 , 5.2 ) Discontinuation syndrome: When discontinuing Escitalopram tablets, reduce dosage gradually whenever possible, and monitor for discontinuation symptoms ( 5.3 ) Seizures: Use with care in patients with a history of seizure ( 5.4 ). Activation of Mania/Hypomania: Screen patients for bipolar disorder. ( 5.5 ). Hyponatremia: Can occur in association with syndrome of inappropriate antidiuretic hormone secretion ( 5.6 ). Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other drugs that affect coagulation may increase risk ( 5.7 ). Interference with Cognitive and Motor Performance: Use caution when operating machinery ( 5.8 ).

Source: FDA prescribing information (DailyMed). Set ID: d75e3b97-1ead-4e7b-9ae3-3626aede1efd. SPL document ID: 5a9933f1-4dfa-bb02-e063-6394a90a1c2d. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Escitalopram 5/10/20 mg tabs (FDA label)

Table 6 presents clinically important drug interactions with Escitalopram tablets. TABLE 6 Clinically Important Drug Interactions with Escitalopram tablets Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs, including Escitalopram tablets, and MAOIs increases the risk of serotonin syndrome.

Source: FDA prescribing information (DailyMed). Set ID: d75e3b97-1ead-4e7b-9ae3-3626aede1efd. SPL document ID: 5a9933f1-4dfa-bb02-e063-6394a90a1c2d. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.